AI Engines For more Details: Perplexity Kagi Labs You
ADHD Treatment: Atomoxetine is a selective norepinephrine reuptake inhibitor (SNRI) that works by increasing the levels of norepinephrine in the brain. It is approved for the treatment of ADHD as it helps improve attention span, concentration, impulse control, and other symptoms associated with ADHD. Atomoxetine is particularly beneficial for individuals who cannot tolerate stimulant medications or those with comorbid conditions such as anxiety disorders or substance abuse.
Symptom Management: Atomoxetine helps reduce the core symptoms of ADHD, including inattention, hyperactivity, and impulsivity. It is effective in both children and adults and is often used as a long-term treatment to manage ADHD symptoms over time.
Executive Functioning: Atomoxetine may also improve executive functioning skills such as organization, planning, and time management, which are commonly impaired in individuals with ADHD. By enhancing these cognitive abilities, atomoxetine can help individuals with ADHD better navigate daily tasks and responsibilities.
Comorbid Conditions: Atomoxetine may be beneficial for individuals with ADHD who also have comorbid conditions such as anxiety disorders, depression, or oppositional defiant disorder (ODD). It can help alleviate symptoms of these conditions and improve overall functioning.
Non-Stimulant Option: Atomoxetine is a non-stimulant medication, which means it does not have the same potential for abuse or dependence as stimulant medications commonly used to treat ADHD, such as methylphenidate or amphetamines. This makes it a preferred option for individuals with a history of substance abuse or those who do not respond well to stimulant therapy.
Side Effects: Common side effects of atomoxetine may include nausea, vomiting, dry mouth, constipation, decreased appetite, insomnia, dizziness, fatigue, and mood swings. In some cases, it may also increase heart rate and blood pressure, so regular monitoring of cardiovascular parameters is recommended during treatment.
Liver Function Monitoring: Atomoxetine has been associated with rare cases of liver injury, including elevated liver enzymes and hepatitis. Therefore, healthcare providers may monitor liver function periodically, especially during the initial months of treatment.
Black Box Warning: Atomoxetine carries a black box warning regarding the increased risk of suicidal ideation in children, adolescents, and young adults with ADHD. Close monitoring for signs of worsening depression or suicidal thoughts is crucial, especially during the early stages of treatment or dosage adjustments.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
species | Escherichia coli | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
ADHD | 0.2 | 0.2 | |
Allergic Rhinitis (Hay Fever) | 0.7 | 0.7 | |
Allergies | 0.8 | 0.1 | 7 |
Allergy to milk products | 0.9 | 0.3 | 2 |
Alzheimer's disease | 0.6 | 0.9 | -0.5 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.5 | 0.8 | -0.6 |
Ankylosing spondylitis | 1 | 0.3 | 2.33 |
Anorexia Nervosa | 0.4 | -0.4 | |
Antiphospholipid syndrome (APS) | 1.3 | 1.3 | |
Asthma | 0.3 | -0.3 | |
Atherosclerosis | 0 | 0 | |
Atrial fibrillation | 0.4 | 0.5 | -0.25 |
Autism | 1 | 1.4 | -0.4 |
benign prostatic hyperplasia | 0.3 | 0.3 | |
Bipolar Disorder | 0.5 | 0.5 | |
Brain Trauma | 0.2 | -0.2 | |
Carcinoma | 0.5 | 0.2 | 1.5 |
Celiac Disease | 1.1 | 0.2 | 4.5 |
Cerebral Palsy | 0 | 0.2 | 0 |
Chronic Fatigue Syndrome | 0.5 | 0.4 | 0.25 |
Chronic Kidney Disease | 0.7 | 0.4 | 0.75 |
Chronic Lyme | 0.2 | -0.2 | |
Chronic Urticaria (Hives) | 1 | 0.1 | 9 |
Coagulation / Micro clot triggering bacteria | 1 | 1 | |
Colorectal Cancer | 1.3 | 0.2 | 5.5 |
Constipation | 0.8 | 0.8 | |
Coronary artery disease | 0.4 | 0.4 | |
COVID-19 | 1.9 | 1.8 | 0.06 |
Crohn's Disease | 1.5 | 0.7 | 1.14 |
cystic fibrosis | 1 | 0.2 | 4 |
deep vein thrombosis | 1 | 1 | |
Depression | 1 | 1.3 | -0.3 |
Eczema | 0.5 | 0.1 | 4 |
Endometriosis | 1.2 | 1.2 | |
Epilepsy | 0.6 | 0.3 | 1 |
Fibromyalgia | 0.2 | -0.2 | |
Functional constipation / chronic idiopathic constipation | 1.5 | 0.2 | 6.5 |
gallstone disease (gsd) | 0.3 | 0.3 | |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | 0.3 | |
Generalized anxiety disorder | 1.2 | 0.2 | 5 |
Graves' disease | 0.2 | 0.2 | |
Halitosis | 0.2 | 0.2 | |
Hashimoto's thyroiditis | 0.2 | 0.2 | 0 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1.2 | 0.3 | 3 |
hypercholesterolemia (High Cholesterol) | 0.1 | -0.1 | |
hyperglycemia | 0.3 | 0.3 | 0 |
Hyperlipidemia (High Blood Fats) | 0 | 0 | |
hypertension (High Blood Pressure | 0.6 | 0.3 | 1 |
Hypoxia | 0.2 | 0.2 | |
IgA nephropathy (IgAN) | 0.8 | -0.8 | |
Inflammatory Bowel Disease | 1.4 | 1 | 0.4 |
Insomnia | 0.2 | 0.2 | 0 |
Intracranial aneurysms | 0.2 | 0.2 | |
Irritable Bowel Syndrome | 1.9 | 0.5 | 2.8 |
Liver Cirrhosis | 0.6 | 0.2 | 2 |
Long COVID | 1.8 | 1 | 0.8 |
Lung Cancer | 0.3 | 0.1 | 2 |
ME/CFS with IBS | 0.2 | -0.2 | |
ME/CFS without IBS | 0.3 | 0.2 | 0.5 |
Metabolic Syndrome | 1.5 | 0.6 | 1.5 |
Mood Disorders | 1 | 1.3 | -0.3 |
multiple chemical sensitivity [MCS] | 0 | 0 | |
Multiple Sclerosis | 0.1 | 0.7 | -6 |
Multiple system atrophy (MSA) | 0.1 | 0.1 | |
Neuropathy (all types) | 0 | 0.3 | 0 |
neuropsychiatric disorders (PANDAS, PANS) | 0.7 | 0.7 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.3 | 0.7 | -1.33 |
Obesity | 0.7 | 0.3 | 1.33 |
obsessive-compulsive disorder | 1.5 | 0.6 | 1.5 |
Osteoarthritis | 0.7 | 0.7 | |
Osteoporosis | 0.5 | 0.2 | 1.5 |
Parkinson's Disease | 0.8 | 0.6 | 0.33 |
Polycystic ovary syndrome | 0.8 | 0 | 0 |
Psoriasis | 0.8 | 0.2 | 3 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.7 | 0.2 | 2.5 |
Schizophrenia | 0.2 | 0.2 | |
Sjögren syndrome | 0.3 | 0.4 | -0.33 |
Sleep Apnea | 0.2 | -0.2 | |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.7 | 0.7 | |
Stress / posttraumatic stress disorder | 0.9 | 0.2 | 3.5 |
Systemic Lupus Erythematosus | 0.8 | 0.8 | |
Tic Disorder | 0.2 | 0.2 | |
Tourette syndrome | 0 | 0.2 | 0 |
Type 1 Diabetes | 0.8 | 0.2 | 3 |
Type 2 Diabetes | 1.7 | 1.9 | -0.12 |
Ulcerative colitis | 1.2 | 0.5 | 1.4 |
Unhealthy Ageing | 0.7 | 0.5 | 0.4 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.